Demographics (intent-to-treat population)
| FF | FP | |||||
| Placebo(n=103) | 200 μg OD (n=99) | 400 μg OD (n=101) | 600 μg OD (n=107) | 800 μg OD (n=102) | 500 μg BD (n=110) | |
| Women, n (%) | 64 (62) | 63 (64) | 62 (61) | 67 (63) | 63 (62) | 68 (62) |
| Age (years) | ||||||
| Mean (SD) | 47.2 (14.03) | 45.7 (15.02) | 47.2 (14.39) | 45.7 (14.38) | 46.6 (14.09) | 46.1 (13.86) |
| Range | 16–78 | 12–77 | 13–70 | 13–75 | 12–76 | 12–74 |
| Race, n (%) | ||||||
| White | 83 (81) | 74 (75) | 80 (79) | 77 (72) | 80 (78) | 83 (76) |
| History of asthma, n (%) | ||||||
| ≥10 years | 63 (61) | 72 (73) | 72 (71) | 75 (70) | 63 (62) | 73 (66) |
| Pre-bronchodilator FEV1 (litre) | ||||||
| Mean (SD) | 2.043 (0.6022) | 2.046 (0.6387) | 2.066 (0.6358) | 2.043 (0.6076) | 2.057 (0.5865) | 2.064 (0.5644) |
| Per cent predicted FEV1 (%) | ||||||
| Mean (SD) | 64.12 (11.133) | 65.08 (11.684) | 66.59 (12.771) | 64.33 (11.983) | 66.00 (12.118) | 65.43 (12.353) |
| Per cent reversibility in FEV1, (%) | ||||||
| Mean (SD) | 26.14 (14.448) | 28.93 (17.305) | 25.53 (13.892) | 28.55 (14.005) | 29.32 (15.409) | 27.02 (15.013) |
| Run-in medication, % (mean dose, μg) | ||||||
| FP | 41 (486.8) | 46 (458.1) | 45 (465.9) | 39 (443.5) | 48 (448.8) | 43 (468.5) |
| Budesonide | 39 (768.7) | 41 (742.2) | 39 (775.9) | 46 (745.7) | 39 (747.7) | 42 (757.7) |
| Beclomethasone dipropionate | 18 (492.2) | 8 (600.0) | 11 (514.5) | 13 (500.9) | 10 (444.0) | 13 (543.6) |
| Ciclesonide | 1 (320) | 4 (300) | 3 (320) | 1 (320) | 1 (400) | 1 (320) |
| Mometasone furoate | 1 (400) | 1 (440) | 2 (440) | 1 (220) | 2 (440) | 1 (440) |
| Smoking status | ||||||
| Never smoked, n (%) | 88 (85) | 83 (84) | 80 (79) | 81 (76) | 78 (76) | 87 (79) |
| Former smoker, n (%) | 15 (15) | 16 (16) | 21 (21) | 26 (24) | 24 (24) | 23 (21) |
| Number of pack years, mean (SD) | 4.9 (2.39) | 5.7 (1.92) | 3.9 (2.57) | 4.4 (3.41) | 3.5 (2.62) | 4.7 (2.74) |
BD, twice daily; FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; FP, fluticasone propionate; OD, once daily.